Recursion Pharmaceuticals (RXRX) Treasury Shares (2020 - 2021)

Recursion Pharmaceuticals (RXRX) has 7 years of Treasury Shares data on file, last reported at $28.6 million in Q1 2026.

• Quarterly Treasury Shares rose 9.14% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (up 9.14% YoY) and the FY2025 annual result came in at $27.5 million, up 0.68% from the prior year.
• Treasury Shares grew to $28.6 million in Q1 2026, from $27.5 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $30.6 million in Q3 2025 to a low of $6.9 million in Q4 2022.
• A 5-year average of $19.2 million and a median of $18.5 million in 2023 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2023 — Treasury Shares surged 153.92% — and 2025, when it grew 0.68%.
• Tracing RXRX's Treasury Shares over 5 years: stood at $6.9 million in 2022, then soared by 120.81% to $15.2 million in 2023, then surged by 79.35% to $27.3 million in 2024, then grew by 0.68% to $27.5 million in 2025, then climbed by 3.91% to $28.6 million in 2026.
• The last three Treasury Shares figures came in at $28.6 million (Q1 2026), $27.5 million (Q4 2025), and $30.6 million (Q3 2025), per Business Quant data.